Does Affinity Health Plan Cover Liraglutide (Saxenda)?

What Is Liraglutide (Saxenda) and Why Does Insurance Coverage Matter?

Liraglutide 3 mg, sold as Saxenda, is a glucagon-like peptide-1 (GLP-1) receptor agonist injected subcutaneously once daily for chronic weight management. It is distinct from Victoza, the 1.2 mg and 1.8 mg formulation approved for type 2 diabetes. At the higher 3 mg dose, liraglutide slows gastric emptying, reduces appetite signaling in the hypothalamus, and lowers caloric intake. The result is clinically meaningful weight loss in most patients who tolerate it.

The cost barrier is significant. At a retail US pharmacy, a 30-day supply of Saxenda runs between $1,300 and $1,500 before any discounts. Without insurance coverage, most patients cannot sustain treatment long enough to reach a metabolic benefit. The SCALE Obesity and Prediabetes trial (N=3,731) demonstrated that 56 weeks of liraglutide 3 mg produced a mean weight loss of 8.4 kg versus 2.8 kg on placebo, with 63.2% of treated patients achieving at least 5% body weight reduction compared with 27.1% on placebo (PubMed). That kind of outcome requires months of uninterrupted therapy, which is only realistic when someone else is sharing the cost.

How GLP-1 Coverage Decisions Are Generally Made

Insurance plans classify anti-obesity medications (AOMs) on their formulary as either covered, non-formulary, or excluded. Many state Medicaid programs historically excluded weight-loss drugs entirely, though that field has shifted as clinical evidence has mounted. Commercial and Medicare Advantage plans set their own coverage policies within federal guardrails.

Affinity Health Plan is a Bronx-originated, New York State-based managed care organization that serves Medicaid, Child Health Plus, Essential Plan, and Medicare Advantage members. Because the majority of Affinity's membership is enrolled in Medicaid managed care, New York State Medicaid rules heavily shape what Affinity must and can cover. Saxenda's coverage status therefore depends on which product line you hold and what the current New York State Medicaid Drug Program says about liraglutide 3 mg.

The Clinical Case for Coverage

The American Association of Clinical Endocrinology (AACE) 2023 guidelines state that pharmacotherapy is indicated for any patient with overweight or obesity who has not achieved sufficient weight loss through lifestyle modification alone, and that GLP-1 receptor agonists are first-line agents when comorbid cardiometabolic disease is present (AACE guidelines summary, Endocrine Practice). The Obesity Society and AACE jointly define clinically meaningful weight loss as at least 5% of body weight, a threshold directly tied to improvements in blood pressure, HbA1c, and lipid profiles.

Framing a prior authorization request around these specific numbers, citing a named guideline, and mapping the patient's comorbidities to each published endpoint gives the authorization the strongest possible foundation.

Affinity Health Plan Product Lines and How Coverage Differs

Affinity Health Plan operates several distinct lines of business, and liraglutide coverage rules are not uniform across them. The product line on your insurance card is the single most important variable.

Medicaid Managed Care (Affinity Health Plan Medicaid)

New York State Medicaid covers liraglutide 3 mg (Saxenda) as a pharmacy benefit, but with prior authorization. The state's Medicaid Drug Program requires documentation of:

• A BMI of 30 kg/m² or higher, OR a BMI of 27 kg/m² or higher with a qualifying comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea.
• A formal diagnosis of obesity or overweight with comorbidity using ICD-10 codes E66.01 (morbid obesity), E66.09 (other obesity), or E66.9 (obesity, unspecified) as appropriate.
• Documentation that structured lifestyle intervention has been attempted, typically a minimum of three to six months of dietary counseling, physical activity guidance, or a formal weight management program.
• No contraindications, including no personal or family history of medullary thyroid carcinoma and no diagnosis of Multiple Endocrine Neoplasia syndrome type 2 (MEN2), which are boxed-warning contraindications on the Saxenda label (FDA prescribing information).

If Affinity follows the New York State Medicaid preferred drug list guidance (which managed care organizations are generally required to do for mandatory benefit categories), Saxenda may sit on a non-preferred tier requiring step therapy through less expensive options first. In practice, this often means documentation that metformin (for patients with prediabetes or type 2 diabetes) or orlistat (for obesity-only patients) was tried and either failed to produce adequate results or was not tolerated.

Essential Plan and Child Health Plus

The Essential Plan is a New York State low-premium plan for adults who earn between 139% and 200% of the federal poverty level. Drug coverage under the Essential Plan tracks New York State Medicaid formulary rules closely, so prior authorization requirements are similar. Child Health Plus covers members under age 19. For adolescents aged 12 to 17 with a BMI at or above the 95th percentile for age and sex, the FDA approved Saxenda in December 2020, and coverage documentation would need to include age-appropriate BMI percentile data rather than absolute kg/m² thresholds (PubMed, SCALE Teens trial).

Medicare Advantage (Affinity Medicare Complete)

This is the most restrictive category. Federal Medicare Part D law historically excluded drugs used for weight loss or weight gain, per 42 CFR 423.100. The Treat and Reduce Obesity Act, if passed, would change this, but as of early 2025 it has not been enacted. However, liraglutide at the 1.8 mg dose (Victoza) may be covered when prescribed for type 2 diabetes. If a member has a formal type 2 diabetes diagnosis AND their prescriber orders Victoza (not Saxenda), coverage through Part D becomes possible under Affinity Medicare Complete. Saxenda specifically, prescribed for weight management only, is likely excluded under most Medicare Advantage plans including Affinity's.

Patients in Affinity Medicare Advantage who want Saxenda should ask their physician whether Victoza is clinically appropriate for their diabetes management, which is a separate clinical question from obesity pharmacotherapy.

Commercial Plans

Affinity has offered commercial products in the past, though its footprint is primarily government-sponsored. Commercial plan formularies vary by employer group. If you hold an Affinity commercial card, call the Member Services number on the back of the card and ask specifically: "Is NDC 00169-4254-13 (Saxenda 18 mg/3 mL pen) on my formulary, what tier is it on, and what are the prior authorization criteria?" Getting this answer in writing (request a fax of the coverage determination criteria) before submitting a PA saves time.

Prior Authorization: Step-by-Step for Liraglutide Through Affinity

Prior authorization is not a denial. It is a documentation review. Physicians and patients who prepare a complete submission on the first attempt have the best odds of approval.

Step 1: Verify Formulary Status Before Prescribing

The prescribing clinician or their staff should check Affinity's online drug lookup tool or call the pharmacy prior authorization line before submitting. Confirming that liraglutide is on the formulary (even on a non-preferred tier) is different from confirming it requires PA. Both pieces of information matter.

Step 2: Assemble the Clinical Documentation

A complete PA packet for Saxenda through Affinity typically includes:

• Current height, weight, and calculated BMI with the date of measurement.
• ICD-10 diagnosis code(s): E66.01, E66.09, or E66.9 for obesity; list comorbidities separately (E11.9 for type 2 diabetes, I10 for hypertension, etc.).
• Documentation of lifestyle intervention: dates of dietary counseling visits, referral to a registered dietitian, participation in a behavioral weight management program, or equivalent.
• Prior pharmacotherapy trial if step therapy applies: drug name, dose, duration, and reason for discontinuation or inadequate response.
• Lab values supporting metabolic risk: fasting glucose, HbA1c, lipid panel, blood pressure readings.
• A clinical note from the prescriber stating that the clinical benefits of treatment outweigh risks for this specific patient.

The FDA's prescribing information for Saxenda specifies that treatment should be discontinued in patients who do not achieve 4% weight loss after 16 weeks at the 3 mg maintenance dose (FDA prescribing information). Including this monitoring plan in the PA request signals to the reviewing pharmacist or medical director that the prescriber understands how to evaluate treatment response appropriately.

Step 3: Submit and Track

Affinity, like all New York State-licensed managed care organizations, must respond to standard PA requests within three business days and urgent requests within 24 hours under New York Insurance Law. Keep the PA submission confirmation number.

Step 4: If Denied, Request the Specific Denial Reason in Writing

Affinity must provide a written denial with the clinical rationale. Common denial reasons include:

• "Drug is non-formulary" (solution: request exception or appeal citing clinical necessity)
• "Step therapy not satisfied" (solution: document prior trial or request step therapy exception under New York law)
• "BMI criteria not met" (solution: verify measurement date, recheck math, resubmit with corrected data)

New York State enacted step therapy override protections under Public Health Law Section 4905-a. A prescriber can request a step therapy exception if the required first-line drug is clinically contraindicated, was previously tried and failed, or if requiring the patient to try it would cause adverse effects. This statute is a real and usable tool, not a theoretical one.

Appealing a Saxenda Denial from Affinity Health Plan

The appeal process for an Affinity liraglutide denial follows a structured path. Use each stage deliberately rather than repeating the same arguments.

Internal Appeal (Level 1)

Submit within 60 days of the denial date. Include everything from the original PA plus any new supporting documents: a letter of medical necessity from the prescriber, peer-reviewed literature (SCALE trial data works well), and specialty society guidelines from AACE or The Obesity Society. Request a peer-to-peer review between the prescriber and Affinity's medical director. These conversations resolve a significant portion of denials before they reach external review.

External Appeal (Level 2)

If the internal appeal fails, New York State offers an External Appeal through the Department of Financial Services (DFS). An independent organization reviews the denial. Affinity must abide by the external reviewer's decision. Submit within 45 days of the internal denial. The external reviewer considers whether the denial is consistent with generally accepted standards of care, which is where AACE 2023 guidelines and the SCALE trial data become the core argument.

Expedited Review

If delay would seriously jeopardize health, request expedited internal review (24-hour turnaround) and expedited external appeal. Patients with worsening metabolic comorbidities or planned surgical procedures may qualify.

Cost Reduction Strategies While Awaiting Coverage

Even while a PA or appeal is in process, patients are not without options for managing cost.

Novo Nordisk Saxenda Savings Card

Novo Nordisk offers a savings program for commercially insured patients, reducing out-of-pocket cost to $25 for a 30-day supply for eligible patients. This program does not apply to Medicaid, Medicare, or any government-funded plan. Eligibility and terms are available at the Novo Nordisk patient assistance page.

Patient Assistance Program (PAP)

Patients with household incomes below approximately 400% of the federal poverty level who lack insurance coverage for Saxenda may qualify for Novo Nordisk's Patient Assistance Program, which provides the medication at no charge. The prescribing office typically submits the PAP application on the patient's behalf.

Compounded Liraglutide

The FDA has raised concerns about compounded versions of GLP-1 agonists. The agency removed semaglutide from the shortage list for most formulations in early 2025, and compounded liraglutide exists in a similarly ambiguous regulatory space. Patients should discuss compounded liraglutide with their physician, understanding that compounded products are not FDA-approved and that quality, sterility, and dosing accuracy are not guaranteed under the same framework as the branded product (FDA compounding FAQ).

Clinical Effectiveness: Why Getting Coverage Is Worth the Effort

The clinical evidence for liraglutide 3 mg in obesity is well-established and quantified.

Weight Loss Outcomes

The SCALE Obesity and Prediabetes trial (N=3,731, 56 weeks) showed that patients on liraglutide 3 mg lost a mean of 8.4 kg versus 2.8 kg on placebo. 63.2% of liraglutide-treated patients achieved at least 5% body weight reduction, and 33.1% lost at least 10%, compared with 10.6% on placebo (PubMed). The SCALE Maintenance trial (N=422) showed that patients who lost at least 5% of body weight on liraglutide during a 12-week run-in, then continued liraglutide for 56 additional weeks, maintained a mean 6.2% additional loss versus a 3.0% regain in the placebo arm (PubMed).

Cardiometabolic Benefits

Liraglutide at the 1.8 mg dose (Victoza) reduced major adverse cardiovascular events by 13% in the LEADER trial (N=9,340, median 3.8 years follow-up) in patients with type 2 diabetes and high cardiovascular risk (NEJM, LEADER trial). While Saxenda's 3 mg obesity indication does not carry a formal cardiovascular outcomes indication, the mechanistic overlap is real and relevant when making the case for medical necessity in patients with coexisting cardiometabolic disease.

Pediatric Data

The SCALE Teens trial (N=251, 56 weeks) enrolled adolescents aged 12 to 17 with a BMI at or above the 95th percentile. Liraglutide produced a mean BMI reduction of 4.64% versus a 1.62% increase in placebo, with 43.3% of treated participants achieving a BMI reduction of at least 5% compared with 18.7% on placebo (PubMed). This data supports PA submissions for Affinity members in the Child Health Plus product line.

What Your Doctor Needs to Write in the Letter of Medical Necessity

A letter of medical necessity is not a form letter. It must be specific to the individual patient. A strong letter from a prescriber includes:

• The patient's exact BMI on a specific date, calculated from measured height and weight.
• A list of active comorbidities with ICD-10 codes and dates of diagnosis.
• A description of the lifestyle intervention attempted: specific program name, number of sessions, duration, and the degree of weight change achieved.
• The prescriber's clinical reasoning for why liraglutide 3 mg is appropriate for this patient at this time, referencing AACE guidelines by name.
• A monitoring plan including the 16-week evaluation point per FDA labeling.
• A statement that there are no contraindications (no personal or family history of MEN2 or medullary thyroid carcinoma).

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has written that "obesity is a chronic disease that requires long-term pharmacological management in the majority of patients, and denial of evidence-based medications on the basis of cost alone represents a failure of the insurance system to recognize established medical science." Citing specialty society positions that obesity pharmacotherapy is disease treatment, not lifestyle enhancement, is a persuasive framing for the medical director reviewing your appeal.

Frequently Asked Questions